Radius Provides Agenda for Today’s R&D Webcast

• Focus: RAD011, an investigational synthetic cannabidiol oral solution
  
  
• Webcast details: 10:00am to 12:00pm for current or prospective investors and sell side analysts
• Objectives: asset overview, science, regulatory, and clinical translation progress since acquisition
  
  

BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Today, Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) will host its Neuroscience R&D webcast to discuss RAD011, our investigational synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas.

The webcast will be held from 10:00am to 12:00pm ET allowing for 1.5 hours of presentations and 30-minutes for Q&A.

The following topics will be covered during the webcast:

Science, Data and Clinical Translation

Liz Messersmith, PhD, Neuroscience

Seizures: Angelman syndrome

Sam Gokhale, MD, MBA, Clinical

David Hebert, PhD, Biometrics

Deirdre Neenan-Smith, Global Advocacy​

Hyperphagia: Prader-Willi syndrome

Tarek El Akkad, MD, Clinical

David Hebert and Deirdre Neenan-Smith

Orphan Designation and IP

Melissa Brand, JD, Intellectual Property

Competitive Landscape and Market Dynamics

Jon Foster, Orphan/Neuro Strategy

Webcast and Conference Call Information

Date: April 5, 2022

Time: 10:00am to 12:00pm ET

Domestic Dial-In Number: 1 (866) 323-7965

International Dial-In Number: 1 (346) 406-0961

Conference ID: 9678881

Webcast Link:

A live audio webcast of the call can be accessed from the Investors section of the Company’s website, .

A replay of the event will be available on April 5 at 3:00pm ET and the audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 9678881. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, .

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.

About RAD011

Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes. The product has purity specifications that meet standardized regulatory and quality control requirements and, compared to the process of developing a plant-derived product, the synthetic manufacturing process usually enables increased consistency and greater precision in the product supply. RAD011 has been assessed in over 125 patients across multiple indications and has potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas. Radius anticipates initiating a seamless pivotal Phase 2/3 study for patients with Prader-Willi syndrome in the first half of 2022 as well as studies for patients with Angelman syndrome and infantile spasms.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the adverse impact the ongoing COVID-19 pandemic is having and is expected to continue to have on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials, preclinical studies, and employees; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products; risks related to our ability to successfully enter into collaboration, partnership, license or similar agreements; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that the results of those trials will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2021 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Relations Contact:

Ethan Holdaway

Email: 

Phone: (617) 583-2017